These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22422830)

  • 1. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
    Zannad F; Stough WG; Pocock SJ; Sleight P; Cushman WC; Cleland JG; McMurray JJ; Lonn E; Geller NL; Wedel H; Abadie E; Alonso-Garcia A; Pitt B
    Eur Heart J; 2012 May; 33(9):1049-57. PubMed ID: 22422830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose control and cardiovascular complications: the VA Diabetes Trial.
    Duckworth WC; McCarren M; Abraira C;
    Diabetes Care; 2001 May; 24(5):942-5. PubMed ID: 11347758
    [No Abstract]   [Full Text] [Related]  

  • 3. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.
    Cavalot F
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():3-8. PubMed ID: 24034513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.
    Jarnert C; Kalani M; Rydén L; Böhm F
    Diab Vasc Dis Res; 2012 Oct; 9(4):287-95. PubMed ID: 22377484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very tight glucose control: May be high risk, low benefit.
    Yudkin JS
    BMJ; 2008 Mar; 336(7646):683. PubMed ID: 18369208
    [No Abstract]   [Full Text] [Related]  

  • 6. Microvascular benefits of hypertension and glucose control in type 2 diabetes.
    van Rensburg BW
    Cardiovasc J Afr; 2008; 19(4):179-80. PubMed ID: 18776957
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
    Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
    BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
    Fisher M
    Int J Clin Pract; 2009 Sep; 63(9):1354-68. PubMed ID: 19691621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intensive therapy in type 2 diabetes. More damage than benefit?].
    Einecke D
    MMW Fortschr Med; 2008 Jun; 150(26-27):12-4. PubMed ID: 18681224
    [No Abstract]   [Full Text] [Related]  

  • 10. Glucose targets for preventing diabetic kidney disease and its progression.
    Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
    Reblin T; Seidel D; Stein D; Görtz A; Lander T
    MMW Fortschr Med; 2003 May; 145(19):41. PubMed ID: 12813977
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study.
    Valenzuela-Garcia LF; Matsuzawa Y; Sara JD; Kwon TG; Lennon RJ; Lerman LO; Ruiz-Salmeron RJ; Lerman A
    Cardiovasc Diabetol; 2015 Aug; 14():106. PubMed ID: 26268857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
    Macisaac RJ; Jerums G
    Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic control and cardiovascular disease: what's a doctor to do?
    Kishore P; Kim SH; Crandall JP
    Curr Diab Rep; 2012 Jun; 12(3):255-64. PubMed ID: 22467273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose lowering and cardiovascular disease: what do we know and what should we do?
    Cheng AY; Leiter LA
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S25-31. PubMed ID: 20489417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
    Dziuba J; Alperin P; Racketa J; Iloeje U; Goswami D; Hardy E; Perlstein I; Grossman HL; Cohen M
    Diabetes Obes Metab; 2014 Jul; 16(7):628-35. PubMed ID: 24443793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
    Gerstein HC; Hart R; Colhoun HM; Diaz R; Lakshmanan M; Botros FT; Probstfield J; Riddle MC; Rydén L; Atisso CM; Dyal L; Hall S; Avezum A; Basile J; Conget I; Cushman WC; Hancu N; Hanefeld M; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Muñoz EGC; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):106-114. PubMed ID: 31924562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
    BMJ; 2011 Nov; 343():d6898. PubMed ID: 22115901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.
    Monte SV; Schentag JJ; Adelman MH; Paladino JA
    J Diabetes Sci Technol; 2010 Mar; 4(2):382-90. PubMed ID: 20307400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis.
    Giugliano D; Chiodini P; Maiorino MI; Bellastella G; Esposito K
    J Endocrinol Invest; 2019 Oct; 42(10):1165-1169. PubMed ID: 30955180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.